Expert Opinion on Investigational Drugs

Journal

Overview
Identity

Publication Venue For

The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. 29:639-644. 2020

Investigational MET inhibitors to treat Renal cell carcinoma. 28:851-860. 2019

Abatacept for the treatment of systemic lupus erythematosus. 25:493-499. 2016

Investigational drugs for hyperuricemia. 24:1013-1030. 2015

Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. 23:305-315. 2014

Optimizing biologically targeted clinical trials for neurofibromatosis. 22:443-462. 2013

Targeting the transforming growth factor-β signaling pathway in human cancer. 19:77-91. 2010

Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. 17:1225-1235. 2008

Oral amphipathic peptides as therapeutic agents. 15:13-21. 2006

Diquafosol tetrasodium: A novel dry eye therapy. 13:47-54. 2004

Diquafosol tetrasodium: a novel dry eye therapy. 13:47-54. 2004

Enfuvirtide. 11:1837-1843. 2002

Molecular advances to treat cancer of the brain. 9:1207-1215. 2000

Tetracyclines for the treatment of rheumatoid arthritis. 9:1491-1498. 2000

Penciclovir/famciclovir: Parent and child in the treatment of herpes virus infections. 3:759-761. 1994

International Standard Serial Number (issn)

1354-3784

Electronic International Standard Serial Number (eissn)

1744-7658